Advertisement

Gichtmittel

  • Bernd Mühlbauer
  • Gerhard Schmidt
Chapter

Zusammenfassung

Die spezifische Arzneitherapie der Gicht umfasst Xanthinoxidasehemmer, Colchicin und Benzbromaron. Standardmittel für die chronische Gicht ist Allopurinol.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Fachinformation Zyloric (2013): http://www.fachinfo.de/suche/fi/002332 (abgerufen 27.06.2014)
  2. Faruque LI, Ehteshami-Afshar A, Wiebe N, Tjosvold L, Homik J, tonelli M (2013): A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. Semin Arthritis Rheum 43: 367–375PubMedCrossRefGoogle Scholar
  3. Janssens H, Lucassen P, Van de Laar F, Janssen M, Van de Lisdonk E (2008): Systemic corticosteroids for acute gout. Cochrane Database Syst Rev. 2008 Apr 16; (2): CD00552–1Google Scholar
  4. Lin KC, Lin HY, Chou P (2000): Community based epidemiological study on hyperuricemia and gout in Kin-Hou. J Rheumatol 27: 1045–1050PubMedGoogle Scholar
  5. Löffler W, Simmonds HA, Gröbner W (1983): Gout and uric acid nephropathy: Some new aspects in diagnosis and treatment. Klin Wochenschr 61: 1223–1239CrossRefGoogle Scholar
  6. Love BL, Barrons R, Veverka A, Snider KM (2010): Urate-lowering therapy for gout: focus on febuxostat. Pharmacotherapy 30: 594–608PubMedCrossRefGoogle Scholar
  7. Sundy JS (2010): Progress in the pharmacotherapy of gout. Curr Opin Rheumatol 22: 188–193PubMedGoogle Scholar
  8. Suresh E, Das P (2012): Recent advances in management of gout. QJM 105: 407–417PubMedCrossRefGoogle Scholar
  9. Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME (2012): Febuxostat for treating chronic gout. Cochrane Database Syst Rev. 2012 Nov 14; 11: CD00865–3Google Scholar
  10. Zhang W, Doherty M, Pascual E, Bardin T, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Lioté F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentão J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gòrska I; EULAR Standing Committee for International Clinical Studies Including Therapeutics (2006a): EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65: 1301–1311Google Scholar
  11. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Lioté F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentão J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gòrska I; EULAR Standing Committee for International Clinical Studies Including Therapeutics (2006b): EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65: 1312–1324Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Bernd Mühlbauer
    • 1
  • Gerhard Schmidt
    • 2
  1. 1.Institut für Klinische PharmakologieBremen
  2. 2.Institut für Pharmakologie und ToxikologieUniversitätGöttingen

Personalised recommendations